Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden

Fernandes, Ancilla W.; Wu, Bingcao; Turner, Ralph M.

doi:10.1080/13696998.2017.1361960

Cited by 20 publications

(23 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is not in itself surprising since the passage from non-metastatic to metastatic disease is known to be associated with a substantial rise in resource utilisation and associated cost. A recent study by Fernandes et al 23 is perhaps more comparable with our own, in that patients with lung cancer with synchronous brain metastases at diagnosis was compared with patients with metastases in other sites. The study was again performed in a US insurance claims database and specifically evaluated patients with EGFR+NSCLC.…”

Section: Discussionsupporting

confidence: 72%

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

Girard

Cozzone

Léotoing³

et al. 2018

ESMO Open

View full text Add to dashboard Cite

PurposeTo assess the incremental cost associated with the management of patients with primary non-squamous non-small cell lung cancer (NSCLC) with brain metastases at the time of diagnosis.MethodsData were extracted from the French Hospital medical information database (Programme de Médicalisation des Systèmes d’Information (PMSI)). Patients with non-squamous NSCLC were identified through a diagnosis of lung cancer and a prescription of bevacizumab or pemetrexed. All such patients hospitalised with lung cancer for the first time in 2013 and with metastases identified at the first hospitalisation were eligible. Two cohorts were identified, one with brain metastases (group B: n=971) and one with metastases at other sites (group A: n=1529). For each patient, total in-hospital medical resource consumption associated with the initial hospitalisation in 2013 and with any follow-up stays in the following 24 months was documented. Costs were attributed from official French national tariffs and expressed in 2017 euros.ResultsThe mean number of hospitalisations per patient in the 24-moth follow-up period was 17 in group A and 21 in group B. >99% of patients in both groups received chemotherapy. 58% of patients in group B and 13% in group A were managed by radiotherapy. 37% in group B and 24% in group A received palliative care. The associated cost was €2979 per patient-month for patients in group B and €2426 for patients in group A, representing a differential cost of €553 per month. Radiotherapy (+€164/month) and palliative care (+€130/month) were the principal drivers of the incremental cost.ConclusionsThe presence of brain metastases at the time of diagnosis of non-squamous NSCLC carries a significant burden, and ways of lowering this burden are needed.

show abstract

Section: Discussionsupporting

confidence: 72%

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

Girard

Cozzone

Léotoing³

et al. 2018

ESMO Open

View full text Add to dashboard Cite

show abstract

“…The method based on the receiver operating characteristic curve [ 9 , 34 , 35 ] is used to evaluate the performance of different discriminant models. The area under the ROC curve (AUC) can objectively reflect the overall performance of different algorithms.…”

Section: Methodsmentioning

confidence: 99%

Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer

et al. 2020

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women. and regrettably, this rate is increasing every year. One of the aspects of all cancers, including breast cancer, is the recurrence of the disease, which causes painful consequences to the patients. Moreover, the practical application of data mining in the field of breast cancer can help to provide some necessary information and knowledge required by physicians for accurate prediction of breast cancer recurrence and better decision-making. The main objective of this study is to compare different data mining algorithms to select the most accurate model for predicting breast cancer recurrence. This study is cross-sectional and data gathering of this research performed from June 2018 to June 2019 from the official statistics of Ministry of Health and Medical Education and the Iran Cancer Research Center for patients with breast cancer who had been followed for a minimum of 5 years from February 2014 to April 2019, including 5471 independent records. After initial pre-processing in dataset and variables, seven new and conventional data mining algorithms have been applied that each one represents one kind of data mining approach. Results show that the C5.0 algorithm possibly could be a helpful tool for the prediction of breast cancer recurrence at the stage of distant recurrence and nonrecurrence, especially in the first to third years. also, LN involvement rate, Her2 value, Tumor size, free or closed tumor margin were found to be the most important features in our dataset to predict breast cancer recurrence.

show abstract

“…The resource and economic burden of BM in NSCLC is substantial [20][21][22][23][24]. Based on a retrospective claims analysis (2008-2016), the estimated adjusted mean total per-patient-permonth (PPPM) cost was $6,029 higher for NSCLC patients with BM than patients with no BM [20].…”

Section: Introductionmentioning

confidence: 99%

“…There is a need for detailed real-world data on the impact of BM compared with other metastases on HRU and costs among patients treated with EGFR-TKIs [21]. An understanding of the economic burden of BM is also reflective of the impact on the physical, social and financial wellbeing of patients with NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US

Kong

Pavilack

Huo

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden

Cited by 20 publications

References 38 publications

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US

Contact Info

Product

Resources

About